Treatment of toxicity from amphetamines, related derivatives, and analogues: A systematic clinical review

John R. Richards, Timothy E. Albertson, Robert W. Derlet, Richard A. Lange, Kent R. Olson, B (Zane) Horowitz

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Background: Overdose of amphetamine, related derivatives, and analogues (ARDA) continues to be a serious worldwide health problem. Patients frequently present to the hospital and require treatment for agitation, psychosis, and hyperadrenegic symptoms leading to pathologic sequelae and mortality. Objective: To review the pharmacologic treatment of agitation, psychosis, and the hyperadrenergic state resulting from ARDA toxicity. Methods: MEDLINE, PsycINFO, and the Cochrane Library were searched from inception to September 2014. Articles on pharmacologic treatment of ARDA-induced agitation, psychosis, and hyperadrenergic symptoms were selected. Evidence was graded using Oxford CEBM. Treatment recommendations were compared to current ACCF/AHA guidelines. Results: The search resulted in 6082 articles with 81 eligible treatment involving 835 human subjects. There were 6 high-quality studies supporting the use of antipsychotics and benzodiazepines for control of agitation and psychosis. There were several case reports detailing the successful use of dexmedetomidine for this indication. There were 9 high-quality studies reporting the overall safety and efficacy of β-blockers for control of hypertension and tachycardia associated with ARDA. There were 3 high-quality studies of calcium channel blockers. There were 2 level I studies of α-blockers and a small number of case reports for nitric oxide-mediated vasodilators. Conclusions: High-quality evidence for pharmacologic treatment of overdose from ARDA is limited but can help guide management of acute agitation, psychosis, tachycardia, and hypertension. The use of butyrophenone and later-generation antipsychotics, benzodiazepines, and β-blockers is recommended based on existing evidence. Future randomized prospective trials are needed to evaluate new agents and further define treatment of these patients.

Original languageEnglish (US)
Pages (from-to)1-13
Number of pages13
JournalDrug and Alcohol Dependence
Volume150
DOIs
StatePublished - May 1 2015
Externally publishedYes

Fingerprint

Amphetamines
Amphetamine
Toxicity
Psychotic Disorders
Derivatives
Benzodiazepines
Antipsychotic Agents
Butyrophenones
Tachycardia
Dexmedetomidine
Therapeutics
Calcium Channel Blockers
Medical problems
Vasodilator Agents
Hypertension
Nitric Oxide
MEDLINE
Libraries
Guidelines
Safety

Keywords

  • Agitation
  • Amphetamines
  • Beta-blockers
  • Hypertension
  • Sedation
  • Tachycardia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Toxicology
  • Pharmacology
  • Pharmacology (medical)
  • Medicine(all)

Cite this

Treatment of toxicity from amphetamines, related derivatives, and analogues : A systematic clinical review. / Richards, John R.; Albertson, Timothy E.; Derlet, Robert W.; Lange, Richard A.; Olson, Kent R.; Horowitz, B (Zane).

In: Drug and Alcohol Dependence, Vol. 150, 01.05.2015, p. 1-13.

Research output: Contribution to journalArticle

Richards, John R. ; Albertson, Timothy E. ; Derlet, Robert W. ; Lange, Richard A. ; Olson, Kent R. ; Horowitz, B (Zane). / Treatment of toxicity from amphetamines, related derivatives, and analogues : A systematic clinical review. In: Drug and Alcohol Dependence. 2015 ; Vol. 150. pp. 1-13.
@article{ef9dec4f2f00458fbe83dcbe14184d82,
title = "Treatment of toxicity from amphetamines, related derivatives, and analogues: A systematic clinical review",
abstract = "Background: Overdose of amphetamine, related derivatives, and analogues (ARDA) continues to be a serious worldwide health problem. Patients frequently present to the hospital and require treatment for agitation, psychosis, and hyperadrenegic symptoms leading to pathologic sequelae and mortality. Objective: To review the pharmacologic treatment of agitation, psychosis, and the hyperadrenergic state resulting from ARDA toxicity. Methods: MEDLINE, PsycINFO, and the Cochrane Library were searched from inception to September 2014. Articles on pharmacologic treatment of ARDA-induced agitation, psychosis, and hyperadrenergic symptoms were selected. Evidence was graded using Oxford CEBM. Treatment recommendations were compared to current ACCF/AHA guidelines. Results: The search resulted in 6082 articles with 81 eligible treatment involving 835 human subjects. There were 6 high-quality studies supporting the use of antipsychotics and benzodiazepines for control of agitation and psychosis. There were several case reports detailing the successful use of dexmedetomidine for this indication. There were 9 high-quality studies reporting the overall safety and efficacy of β-blockers for control of hypertension and tachycardia associated with ARDA. There were 3 high-quality studies of calcium channel blockers. There were 2 level I studies of α-blockers and a small number of case reports for nitric oxide-mediated vasodilators. Conclusions: High-quality evidence for pharmacologic treatment of overdose from ARDA is limited but can help guide management of acute agitation, psychosis, tachycardia, and hypertension. The use of butyrophenone and later-generation antipsychotics, benzodiazepines, and β-blockers is recommended based on existing evidence. Future randomized prospective trials are needed to evaluate new agents and further define treatment of these patients.",
keywords = "Agitation, Amphetamines, Beta-blockers, Hypertension, Sedation, Tachycardia",
author = "Richards, {John R.} and Albertson, {Timothy E.} and Derlet, {Robert W.} and Lange, {Richard A.} and Olson, {Kent R.} and Horowitz, {B (Zane)}",
year = "2015",
month = "5",
day = "1",
doi = "10.1016/j.drugalcdep.2015.01.040",
language = "English (US)",
volume = "150",
pages = "1--13",
journal = "Drug and Alcohol Dependence",
issn = "0376-8716",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Treatment of toxicity from amphetamines, related derivatives, and analogues

T2 - A systematic clinical review

AU - Richards, John R.

AU - Albertson, Timothy E.

AU - Derlet, Robert W.

AU - Lange, Richard A.

AU - Olson, Kent R.

AU - Horowitz, B (Zane)

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Background: Overdose of amphetamine, related derivatives, and analogues (ARDA) continues to be a serious worldwide health problem. Patients frequently present to the hospital and require treatment for agitation, psychosis, and hyperadrenegic symptoms leading to pathologic sequelae and mortality. Objective: To review the pharmacologic treatment of agitation, psychosis, and the hyperadrenergic state resulting from ARDA toxicity. Methods: MEDLINE, PsycINFO, and the Cochrane Library were searched from inception to September 2014. Articles on pharmacologic treatment of ARDA-induced agitation, psychosis, and hyperadrenergic symptoms were selected. Evidence was graded using Oxford CEBM. Treatment recommendations were compared to current ACCF/AHA guidelines. Results: The search resulted in 6082 articles with 81 eligible treatment involving 835 human subjects. There were 6 high-quality studies supporting the use of antipsychotics and benzodiazepines for control of agitation and psychosis. There were several case reports detailing the successful use of dexmedetomidine for this indication. There were 9 high-quality studies reporting the overall safety and efficacy of β-blockers for control of hypertension and tachycardia associated with ARDA. There were 3 high-quality studies of calcium channel blockers. There were 2 level I studies of α-blockers and a small number of case reports for nitric oxide-mediated vasodilators. Conclusions: High-quality evidence for pharmacologic treatment of overdose from ARDA is limited but can help guide management of acute agitation, psychosis, tachycardia, and hypertension. The use of butyrophenone and later-generation antipsychotics, benzodiazepines, and β-blockers is recommended based on existing evidence. Future randomized prospective trials are needed to evaluate new agents and further define treatment of these patients.

AB - Background: Overdose of amphetamine, related derivatives, and analogues (ARDA) continues to be a serious worldwide health problem. Patients frequently present to the hospital and require treatment for agitation, psychosis, and hyperadrenegic symptoms leading to pathologic sequelae and mortality. Objective: To review the pharmacologic treatment of agitation, psychosis, and the hyperadrenergic state resulting from ARDA toxicity. Methods: MEDLINE, PsycINFO, and the Cochrane Library were searched from inception to September 2014. Articles on pharmacologic treatment of ARDA-induced agitation, psychosis, and hyperadrenergic symptoms were selected. Evidence was graded using Oxford CEBM. Treatment recommendations were compared to current ACCF/AHA guidelines. Results: The search resulted in 6082 articles with 81 eligible treatment involving 835 human subjects. There were 6 high-quality studies supporting the use of antipsychotics and benzodiazepines for control of agitation and psychosis. There were several case reports detailing the successful use of dexmedetomidine for this indication. There were 9 high-quality studies reporting the overall safety and efficacy of β-blockers for control of hypertension and tachycardia associated with ARDA. There were 3 high-quality studies of calcium channel blockers. There were 2 level I studies of α-blockers and a small number of case reports for nitric oxide-mediated vasodilators. Conclusions: High-quality evidence for pharmacologic treatment of overdose from ARDA is limited but can help guide management of acute agitation, psychosis, tachycardia, and hypertension. The use of butyrophenone and later-generation antipsychotics, benzodiazepines, and β-blockers is recommended based on existing evidence. Future randomized prospective trials are needed to evaluate new agents and further define treatment of these patients.

KW - Agitation

KW - Amphetamines

KW - Beta-blockers

KW - Hypertension

KW - Sedation

KW - Tachycardia

UR - http://www.scopus.com/inward/record.url?scp=84926416101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926416101&partnerID=8YFLogxK

U2 - 10.1016/j.drugalcdep.2015.01.040

DO - 10.1016/j.drugalcdep.2015.01.040

M3 - Article

C2 - 25724076

AN - SCOPUS:84926416101

VL - 150

SP - 1

EP - 13

JO - Drug and Alcohol Dependence

JF - Drug and Alcohol Dependence

SN - 0376-8716

ER -